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Abstract MicroRNAs (miRNAs) exhibit many functions
in biological activities. Recent studies have shown that
miRNAs exist outside cells and are transferred between
cells. Extracellular miRNAs are protected from ribonu-
cleases found in body fluids through binding to specific
proteins or by being encapsulated in lipid bilayer vesicles.
Here, we review the mechanisms of the secretion and
uptake as well as the functions of extracellular miRNAs,
particularly those encapsulated in extracellular vesicles.
Extracellular vesicles are related to cancer progression, and
some miRNAs in extracellular vesicles are associated with
cancer cells. We describe the transfer of cancer-related
miRNAs between cancer cells and non-cancerous cells.
Finally, we discuss the anticipated applications of miRNAs
present in extracellular vesicles in diagnostics and
therapeutics.
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Introduction
MicroRNAs (miRNAs) are small (18–25 nt) non-coding
RNAs that repress gene expression through post-tran-
scriptional degradation or translational repression [1]. The
first identified miRNA, lin-4, was found in Caenorhabditis
elegans in 1993 and was suggested to regulate transcription
via an RNA–RNA interaction in the 30 untranslated region
(UTR) of lin-14 mRNA [2]. miRNAs are conserved in a
large number of species of living organisms [3, 4]. So far,
2,588 miRNAs have been identified in Homo sapiens [5].
The most fundamental function of miRNAs is RNA
interference (RNAi), which is a mechanism of silencing
gene expression by degrading mRNAs with a comple-
mentary sequence. The phenomenon of silencing by small
RNA fragments was first observed in petunia plants in 1990
(referred to as ‘cosuppression’) [6, 7] and subsequently in
Neurospora crassa in 1992 (referred to as ‘quelling’) [8],
but the underlying molecular mechanism was unclear. In
1998, Mello and Fire first described the RNAi mechanism
in studies on C. elegans using short interfering RNAs
(siRNAs) [9, 10]. Since then, RNAi has been shown to be
conserved in almost all species and to possess a common,
fundamental mechanism of regulating gene expression.
The discovery of RNAi has also accelerated molecular
biology research by leading to the development of genetic
technologies to knock down any desired gene.
The molecular mechanism of RNAi has been explained
in detail previously (reviewed in [11]). In brief, a miRNA
is processed from a stem-loop sequence of *70 nt (pre-
mir), which is excised from a longer primary transcript
(pri-mir). The pre-mir is exported to the cytoplasm to be
cleaved into double-stranded RNA to form the miRNA by
Dicer, an RNase III enzyme. The double-stranded miRNA
is incorporated into the miRISC complex, and the leading
strand of the miRNA is retained in the complex. miRNAs
bind to a perfect complementary or a nearly perfect com-
plementary sequence within a mRNA, and the sequence is
cleaved by the miRISC complex.
Our knowledge of the importance of miRNAs in various
bioactivities has been increasing. In addition to RNAi,
miRNA regulates transcriptional levels in another manner:
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through inhibition of translation by binding to the 30-UTR
[12] and 50-UTR of mRNAs [13]. Recent studies have also
shown that miRNAs recognize coding regions [14].
Because miRNAs recognize sequences with imperfect
pairings, a single miRNA can target a broad range of
mRNAs with nearly complementary sequences, thereby
increasing its impact on transcriptional regulation. Fur-
thermore, miRNAs are involved in gene silencing through
chromatin remodeling [15], which implies that miRNAs
also play a role in epigenetic regulation. miRNAs have also
been suggested to regulate DNA methylation and telomere
recombination [16]. Through these mechanisms, miRNAs
are involved in many physiological roles and develop-
mental processes as well as in the progression of some
diseases, such as cancer [17]. A reduction of tumor-sup-
pressive miRNAs or overexpression of tumor-promoting
miRNAs has been observed in cancer progression [18].
These post-transcriptional regulation and the other func-
tions of miRNAs are all carried out in the cytoplasm or
nuclear envelope; that is, inside the cell. However, miRNAs
have also been found outside cells in various body fluids,
such as serum, saliva, urine, breast milk, and tears [19–
22]. These miRNAs are spontaneously secreted from cells.
Moreover, these extracellular miRNAs function in recipient
cells, indicating roles in cell–cell communication. Extra-
cellular miRNAs also have been suggested to be related to
several diseases, including cancer. In this review, we
describe cell–cell communication between cancer cells and
non-cancerous cells via miRNA packaged in extracellular
vesicles and potential applications for therapeutic strategies.
Extracellular miRNAs
RNAs have been discovered outside cells, even though
RNAs have generally been thought to function inside cells.
The following types of RNA have been found in extracel-
lular environments: mRNA, tRNA, miRNA, small
interfering RNA (siRNA), and lncRNA; however, almost no
rRNA was detected in studies on a mast cell line and glio-
blastoma [23, 24]. In humans, miRNAs have been found in
several body fluids, such as blood plasma [22], urine [25],
saliva [26], semen [27] breast milk [28], and cerebrospinal
fluid [29]. The detection of miRNAs outside cells drew
interest because some body fluids, such as saliva, milk, and
urine, contain a high concentration of nucleases [30].
Indeed, miRNAs from serum were shown to remain stable
after several treatments that degraded most RNAs [31].
These reports suggested that extracellular miRNAs are
protected from ribonucleases in some manner. Several
mechanisms for preventing the degradation of miRNAs have
been demonstrated. One possible mechanism used to protect
miRNAs from degradation is RNA-binding proteins, such as
Argonaute 2 (Ago2) [32], other Ago proteins (Ago1 [33],
Ago3, Ago4 [34]), and nucleophosmin 1 [35]. High-density
lipoproteins (HDLs) and low-density lipoproteins (LDLs)
also interact with and transfer miRNAs to cells [36]. An
alternative mechanism used to protect miRNAs from deg-
radation involves the packaging of miRNAs in small, lipid
bilayer vesicles, referred to as extracellular vesicles (EVs)
[23]. Previously, we have found that approximately 30 % of
extracellular miRNAs are packaged into EVs in both cell
culture and sera (unpublished). These two mechanisms are
independent according to a study showing that Ago2 trans-
fers miRNAs independent of EVs based on differential
centrifugation and size-exclusion chromatography analyses
[32]. However, some reports discuss the possibility that
extracellular miRNAs associated with proteins are not
spontaneously secreted but represent cellular residue
released from dead cells [34]. In addition, evidence of the
uptake of protein-associated miRNAs and their function in
the recipient cells remains scarce. The mechanisms and
functions of protein-bound miRNAs should be elucidated to
demonstrate the biological role of miRNAs associated with
protein and to determine whether extracellular miRNAs
protected by proteins and miRNAs encapsulated in EVs
exhibit different secretion pathways and functions. This
review primarily addresses miRNAs secreted in vesicular
form, for which the mechanism has been more clearly
elucidated.
Extracellular vesicles (EVs)
Extracellular vesicle is a comprehensive term for lipid bi-
layered vesicles that exist outside cells [37]. EVs include
apoptotic bodies (800–5,000 nm diameter), microvesicles
(50–1,000 nm diameter), and exosomes (40–100 nm
diameter) [38, 39]. These EVs have different origins and
properties. Apoptotic bodies are released from the cell
surface during the process of apoptosis [40]. Microvesicles
are also formed by budding directly from the cellular
membrane [41], whereas exosomes first bud into a mul-
tivesicular body (MVB), which is an intracellular
compartment, and are then secreted to the extracellular
milieu [39]. Different RNA profiles have been demon-
strated for each type of vesicle [42]. Apoptotic bodies
primarily contain rRNA, and microvesicles carry little
RNA, except for microvesicles from TF-1 cell culture.
Exosomes contain mRNA and miRNA, but little rRNA
[42]. Proteins on the surface are also different among the
three vesicles. CD9 and CD63 are recognized as potential
markers of exosomes, ARF6 and VCAMP2 are proposed as
microvesicle markers, and TSP and C3b are accepted as
markers for apoptotic bodies (reviewed in [43]). With
respect to lipid compositions, exosomes have low
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phosphatidylserine (PS) at outer leaflet, while microvesi-
cles and apoptotic bodies contain high amount of PS [44].
Enrichment of ceramide is one of the characteristics of
exosomes [45].
However, we must consider that the currently used
techniques are inadequate for collecting each type of EV
separately [46]. In addition, the nomenclature of exosomes
is confusing [37]. In 1983, two groups reported that
reticulocytes release transferrin receptors associated with
small vesicles [47, 48]. These authors showed that the
vesicles were formed inside multivesicular endosomes. The
term ‘exosome’ was subsequently applied to the vesicles in
1987 [49]. However, in 1981, microvesicles released to cell
cultures from the cell membrane of normal and neoplastic
cell lines with 50-nucleotidase activity were referred to as
‘exosomes’ [50]. ‘Exosome’ is also used to refer to the
exoribonucleases identified in Saccharomyces cerevisiae
[51]. The International Society of Extracellular Vesicles
recommended the nomenclature ‘EVs’ as a generic term
for all secreted vesicles, and the terms should be defined
clearly before use [37]. In this review, we use the term
‘EVs’ for collective extracellular vesicles, and ‘exosomes’
for extracellular vesicles which are formed by budding into
MVBs.
EVs have long been thought of as no more than a gar-
bage can for cells to discard unwanted components [52].
mRNAs, DNAs, and proteins have been detected within
these vesicles [53], and miRNAs were discovered inside
EVs decades later, in 2007 [23]. Valadi et al. identified
miRNAs as well as mRNAs inside EVs from mouse and
human mast cell lines and proved that these nucleic acids
are functional in the recipient cells. These findings drew
much attention to EVs, and miRNAs were recognized as a
new regulatory component in gene expression. Based on
the reports accumulated to date, almost all cells are now
considered to release EVs [23].
Secretion of miRNAs packed in exosomes
Studies examining the molecular mechanisms of exosomes
release from one cell and their uptake by other cells are
ongoing (described in Fig. 1). Exosomes are formed by
budding into early endosomes to form MVBs. MVBs fuse
with the cellular membrane or lysosomes. When fused with
the plasma membrane, internal exosomes are released
outside the cell [54].
The mechanism underlying the formation of exosomes
into MVBs is controversial. The biogenesis of exosomes
was first suggested to be associated with the endosomal
sorting complex required for transport (ESCRT) [55].
ESCRT-related proteins, such as HRS (ESCRT-0),
TSG101 (ESCRT-I), CHMP4 (ESCRT-II), ALIX and
VPS4 (ESCRT-III), have been shown to be recruited to the
cytosolic sides of MVBs to form exosomes (summarized in
[56]). However, a recent report demonstrated that mam-
malian cells without key ESCRT components could still
form MVBs [57]. Some studies have revealed some exo-
some formation that is independent of ESCRT, and this
process depends on several molecules, such as ceramide
[45] or tetraspanins [58]. Neutral sphingomyelinase 2
(nSMase2), a rate-limiting enzyme in ceramide biosyn-
thesis [59], affects the secretion of miRNAs [60]. The
nSMase2-dependent transfer of miRNAs via exosomes
contributes to cancer metastasis in mouse breast cancer
[59]. Tetraspanins are enriched on the surface of exosomes,
and some of these proteins, such as CD9, CD63, and CD81,
are also used as marker proteins of the exosome. Bone
marrow dendritic cells from CD9 knockout mice were
incapable to secrete exosome [61], while CD81 seemed not
effect exosome secretion in lymphocytes [62] (reviewed in
[58]). CD63 has been suggested to be instrumental in the
formation of internal vesicles in melanocytes [63].
MVBs are sorted in two ways: through fusion with
lysosomes or through fusion with the cellular membrane to
secrete exosomes [56]. During the secretion steps, RAB
proteins (RAB11, RAB27, and RAB35) have been shown
to be involved in the transport of MVBs to the plasma
membrane and in exosome secretion [56]. In addition,
SNAREs have been suggested to be involved in MVB
fusion with the plasma membrane [46].
Within exosomes from human, more than 700 miRNAs
have been identified to date, together with thousands of
proteins, DNAs, and mRNAs (Vesiclepedia and EVpedia)
[64–67]. Several studies using microarrays or next-gener-
ation sequencing have identified a dozens of non-coding
RNAs in exosomes froma single cell line [68, 69]. How-
ever, based on the size of exosomes (*100 nm), not all
miRNAs are packaged into a single exosome. Exosomes
from the same cell line are likely to exhibit different
contents [70, 71].
The miRNA concentration within exosomes appears to
partially depend on the concentration inside the cell. For
example, exosomes secreted from cells overexpressing a
certain miRNAs contain more of the overexpressed miR-
NAs [72]. However, many reports have shown that the
profiles of miRNAs in exosomes are different from those of
exosome-producing cells, suggesting that miRNAs are
selectively packaged into exosomes. For example, although
rRNA accounts for the majority of the RNA in a cell,
almost no rRNA was detected in studies examining exo-
somes from a mast cell line and glioblastoma [23, 24]. The
first paper detecting miRNAs in exosomes showed that
only a fraction of miRNAs from all miRNAs expressed in
the cells were detected in exosomes [23]. Moreover, some
miRNAs were found at higher levels in exosomes than in
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the cells [23]. In MCF7 cells (breast cancer cells), only 2 %
of many miRNAs including miR-720, the most abundant
miRNA in the cell, were released into the environment,
whereas miR-451 and miR-107 were secreted at higher
levels [73]. However, the molecules responsible for
selectively packaging miRNAs into exosomes remain to be
identified. Villarroya-Beltri et al. [74] discussed that su-
moylated form of the heterogenous ribonucleoprotein
A2B1 (hnRNPA2B1) would load miRNAs into exosomes
through EXOmotif (GGAG) in the miRNAs. The mecha-
nisms of miRNA secretion can be applied to design
exosomes that contain specific miRNAs. This technique
would enable us to produce exosomes carrying tumor-
suppressive miRNAs for cancer therapy.
Uptake of exosomes into target cells
Released exosomes may be taken up by nearby cells, or
they may reach cells at a distance through the blood or
lymph system. However, the mechanism of uptake is more
obscure than the secretion mechanism. The mechanisms of
uptake suggested to date include endocytic pathways, such
as endocytosis, phagocytosis and macropinocytosis, and
direct fusion with the cellular membrane [54, 75–78]
(Fig. 1). Escrevente et al. [79] showed that proteinase K
treatment of exosomes significantly reduced uptake by
ovarian cancer cells. The results indicate that surface pro-
teins on exosomes take part in the uptake of exosomes.
Mulcahy et al. suggested in a review that proteins on the
surface of exosomes such as tetraspanins and lectins are
involved in exosome uptake. They also suggested that
integrins, proteoglycans, and lectin receptor proteins on the
cell surface may serve as receptor of exosome surface
protein for uptake (reviewed in [80]).
Concerning the direct fusion mechanism, Parolini et al.
showed, using fluorescently labeled exosomes from mela-
noma cells, that lower pH, which is linked to tumor
malignancy, increases exosome release and uptake. The
authors indicated that a high rigidity and a high content of
sphingomyelin/ganglioside GM3 and caveolin-1 in exosomes
are responsible for accelerated fusion under a low pH [78].
Endocytic uptake was first suggested in dendritic cells
[81]. Some reports have identified the molecules involved in
exosome uptake through endocytosis. Dynamin 2 (Dyn2),
which is necessary for clathrin- and caveolin-dependent
endocytosis, was shown to be essential for the internaliza-
tion of exosomes, suggesting that exosomes are taken up via
clathrin- or caveolin-dependent endocytosis [75]. Heparan
sulfate proteoglycans (HSPGs) have been suggested to serve
Fig. 1 Schematic representation of the secretion, transfer, and uptake
of exosomes. Exosomes are formed by budding into early endosomes
to form MVBs. The internal vesicles are secreted outside the cells via
MVB fusion with the cellular membrane. The released exosomes are
taken up by neighboring cells or distant cells. Exosome internalization
occurs through either direct fusion or endocytic pathways. The
exosomes are carried outside the cells for lipid recycling
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as the receptors of cancer cell-derived exosomes in glio-
blastoma patients [82]. This finding suggests a mechanism
similar to a virus entering a cell, as HSPGs are also known
to be involved in viral entry [82]. In addition, exosomes
from glioblastoma cells are internalized into HUVECs
through lipid raft-mediated endocytosis and are negatively
regulated by caveolin-1 (CAV1), although CAV1 was not
found to co-localize with exosomes. CAV1 was suggested to
have negative effect on exosome internalization through
extracellular signal-regulated kinase-1/2 (ERK1/2)- and heat
shock protein 27 (HSP27) signaling [83].
Tian et al. [84] visualized the cellular uptake and
intracellular trafficking of exosomes in vitro at a single-
particle level and indicated that exosomes may enter cells
through endocytic pathways. First, exosomes are trans-
ported along the cell periphery, potentially by actin
filaments. Exosomes are then carried to perinuclear
regions, possibly on microtubules via dynein-dependent
transport, to be trapped in large vesicles. At the same time,
exosomes are transferred from the perinuclear space to the
cell surface, which may occur along microtubules via ki-
nesins for lipid recycling. The proteins in exosomes were
observed to be released from exosomes within 3 h after
endocytosis and through the fusion of endosomes or late
endosomes in an acidified environment. Then, the proteins
are sorted into lysosomes. When and how miRNAs are
released to functionally regulate transcription in the cytosol
has not been demonstrated.
Whether exosomes are selectively taken up by certain
cells has been investigated. Many reports have suggested
that exosomes are delivered specifically to cells [85].
Unidirectional transfer of miRNAs from T cells to antigen-
presenting cells via exosomes has been reported [72].
Proteins at the surface of exosomes seemed to be involved
in target-specific internalization into cells. However, the
primary mechanism by which exosomes selectively inter-
act with target cells has not been elucidated.
After exosomes are uptaken by recipient cells, exosome-
transferred miRNAs function in transcriptional regulation
in recipient cells [53]. In 2010, four independent groups
showed that miRNAs transferred to recipient cells function
to repress the expression of target genes [60, 86–88]. As
exosomes are thought to be secreted from all types of cells,
these vesicles are likely to be responsible for important
physiological functions through cell–cell communication.
Indeed, reports have shown that exosomes are involved in
physiological functions, for example, in immune response
(T cells, B cell, and dendritic immune cells) [28, 72] and
neuron-glia communication [89]. However, the molecular
mechanisms of how exosomes act in physiological func-
tions have remained elusive because of the limits of the
experimental methods for detection and for tracking exo-
somes from specific cells in vivo.
Cancer-promoting EVs and their miRNAs
The expression levels of miRNAs are dynamically
altered in cancer cells compared to normal cells [86].
Many miRNAs have been reported to play roles in both
accelerating and inhibiting of cancer progression [20,
87]. These cancer-related miRNAs have been detected
not only in cancer cells but also in cancer-derived EVs
(reviewed in [52]). Indeed, increasing evidences sug-
gested that EVs contribute to malignancy in cancer [90].
Cancer cells release more EVs than normal cells [91,
92]. Tumor-derived EVs are recognized as antigens by
dendritic cells, inducing antitumor immune responses
[70]; at the same time, cancer-derived EVs are associated
with tumor malignancy and progression. Inhibition of EV
secretion using a short hairpin RNA targeting RAB27A,
a protein involved in intracellular trafficking of EVs, led
to poor development of subcutaneously injected 4T1
mouse mammary tumor cells [93]. Furthermore, inhibi-
tion of EV secretion through nSMase2 knockdown
inhibited vascular formation in primary tumors, and the
opposite response was observed after nSMase2 overex-
pression [59]. Here, we describe some of the cancer
progression-related miRNAs detected in EVs thus far
(Table 1).
Tumor proliferation and angiogenesis
Communication between tumor cells and their surrounding
microenvironment has a large impact on tumor prolifera-
tion [94]. Cancer cells modify their microenvironment by
transferring miRNAs that are suitable for their growth via
EVs. miR-210 is a major cancer-related miRNA that is
induced in hypoxia [95]. In EVs from highly metastatic
breast cancer, miR-210 was found to be enriched and to be
responsible for the induction of angiogenesis in the tumor
microenvironment [59]. Endothelial cells that received
tumor-derived EVs underwent vascular formation [59].
miR-9 is delivered by melanoma-derived EVs into endo-
thelial cells and promotes endothelial cell migration and
angiogenesis by reducing SOCS5 and activating the JAK-
STAT pathway [96]. miR-105 in EVs from breast cancer
cells targets the tight junction protein ZO-1, leading to
destruction of vascular endothelial barriers and promotes
metastasis [97].
Cancer cells release miRNAs to decrease the expression
of tumor suppressor genes. miR-21, which contributes to
the development of cancer, has also been identified in
cancer-derived EVs [98]. miR-21 represses PTEN [99] and
PDCD4 [100], which are known tumor suppressor genes.
miR-21 has been detected in EVs from breast cancer cells
[73], glioblastoma [98], and malignant ascites [101]. Let-7
miRNA, which was found to play tumor-suppressive roles
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in early studies [102], accumulates in secreted EVs from a
metastatic gastric cancer cell line, AZ-P7a, compared with
low-metastatic cells and other types of cancer cell lines
[103]. Let-7 miRNA downregulates oncogenes such as
RAS and HMGA2, suggesting that AZ-P7a cells release let-
7 miRNA via EVs to maintain their oncogenesis [103].
Tumor dormancy
Breast cancer is known to present especially late recurrence
after 10–20 years [104]. EVs from bone marrow mesen-
chymal stem cells (BM-MSCs) are thought to enable breast
cancer cells in the bone marrow to be dormant for 10 years,
which is considered the main cause of breast cancer reoc-
currence after a long period [105]. miR-23b in EVs from
BM-MSCs were suggested to suppress MARCS, which
encodes myristoylated alanine-rich C kinase substrate and
promotes cell cycling and motility [105].
Transfer of drug resistance
In cancer, EVs also contribute to malignancy by enhancing
the drug resistance of the recipient cells. Using the MCF-7
cell line, Chen et al. showed that EVs from drug-resistant
breast cancer cells enhance drug resistance in proximate
cells by modulating the cell cycle and drug-induced
apoptosis. Through microarray analyses and confirmation
via quantitative real-time PCR, miR-100, miR-222, and
miR-30a were shown to be increased in EVs from drug-
resistant breast cancer cells, suggesting that these miRNAs
contribute to the transfer of drug resistance [106].
Suppression of the immune system
During cancer progression, the immune system attempts to
remove cancer cells. However, many reports have shown
that EVs released from cancer cells can repress the immune
system through multiple pathways [107, 108]. In most
cases, proteins within and on the surface of EVs play roles
in suppression; however, miR-21 and miR-29a in EVs
derived from lung cancer cells were observed to be able to
bind to Toll-like receptors on surrounding immune cells to
trigger an inflammatory response, leading to the secretion
of pro-metastatic inflammatory cytokines [109]. Cancer
cells also take advantage of immune cell-derived EVs.
Tumor-associated macrophages were shown to release EVs
Table 1 Cancer-related miRNAs in EVs
Function Secretion cells Target cells miRNA miRNA targets References
Angiogenesis Mouse mammary breast
cancer (4T1)
Endothelial cells (in vivo, in vitro) miR-210 [52]
Melanoma Endothelial cells miR-9 SOCS5 [96]
Breast cancer cells
(MDA-MB-231)















Let-7 RAS, HMGA2 [103]
Dormancy Bone mallow mesenchymal
stem cells
Breast cancer cell (MDA-MB-231) miR-23b MARCS [105]











Immune suppression HEK-293 Murine macrophage miR-21, miR-29a Directly bind Toll-like
receptor
[109]
Promote invasiveness IL-4-activated M2
macrophages
Breast cancer cells (SKBR3 and
MDA-MB-231)
miR-223 MEF2C [110]
Metastasis Colorectal cancer miR-21 PDCD4 [100]
Premetastatic niche
formation







Lymph node stroma cells, lung
fibroblasts
miR-494, miR-542-3p Cadherin-17 [113]
Tumor suppressive Prostate epithelial cells
(PNT-2)





containing miR-223, which is specific for IL-4-activated
M2 macrophages. miR-223 transferred to breast cancer
cells targets the 30-UTR of MEF2C, a myocyte enhancer
factor. The reduction of MEF2C is linked to nuclear
accumulation of the function of b-catenin to promote the
invasiveness of the SKBR3 and MDA-MB-231 breast
cancer cell lines [110].
Tumor metastasis
Extracellular vesicles derived from cancer cells have also
been suggested to contribute to metastasis by modifying
the environment of distant organs. To form colonies in
metastatic organs, cancer cells must overcome several
barriers, one of which is surviving and proliferating in
metastatic organs. Tumor cells have been suggested to
condition the metastatic area beforehand using EVs to form
an environment that is suitable for growing cancer cells.
The microarea conditioned by EVs is referred to as the
premetastatic niche [111]. Some miRNAs involved in the
formation of the premetastatic niche have been identified.
In renal cancer stem cells, several miRNAs (miR-200c,
miR-92, miR-141, miR-29a, miR-650, and miR-151) found
in EVs are related to the formation of the lung premeta-
static niche and lead to tumor invasion and metastasis, in
addition to inducing angiogenesis [112]. In EVs from
metastatic rat adenocarcinoma, miR-494 and miR-542-3p
were shown to be increased and to prepare premetastatic
organ stroma cells by affecting proteases, adhesion mol-
ecules, chemokine ligands, cell cycle- and angiogenesis-
promoting genes, and the oxidative stress response [113].
EVs from non-cancerous cells with tumor-suppressive
effects
Many reports have shown that EVs from cancer cells con-
tribute to cancer progression. However, normal cells also
release EVs that play inhibitory roles in cancer progression,
although few transferring tumor-suppressive miRNAs have
been reported to inhibit the proliferation of cancer cells.
Epithelial prostate cells, PNT-2, secrete EVs containingmiR-
143, which repressed proliferation of prostate cancer cells,
PC-3M [114]. Other tumor-suppressive miRNAs, including
miR-15a, the miR-200 family, miR-148a, miR-193b, miR-
126, and miR-205, have also been identified. miR-143
downregulates KRAS and ERK5 and represses the prolifera-
tion of metastatic prostate cancer PC-3M cells [114]. Some
reports have indicated that immune cells release tumor-sup-
pressive EVs. For example, NK cells release EVs containing
perforin, CD56, and granzyme B to inhibit tumor growth
[115].However, in theseEVs, only proteins, and notmiRNAs,
have been identified as effective components thus far.
However, it is likely that immune cell-derived EVs also
contain miRNAs, which contribute to suppress tumor
progression.
miRNAs in EVs as biomarkers for diagnostic,
prognostic, and therapeutic targets
Extracellular miRNAs are anticipated to be useful as bio-
markers because miRNAs in vesicles can be detected in
body fluids (reviewed elsewhere, in [91, 116]), such as
sera, urine, and saliva. In addition, EVs reflect different
expression profiles in normal cells and cancerous cells in
ovarian cancer [91], or cancer-derived exosomes selec-
tively contain specific miRNAs in cells [73]. The profiling
of miRNAs in EVs has become easier due to the devel-
opment of microarray and next-generation deep-
sequencing technologies [117].
Diagnosis and prognosis
miRNAs found in EVs may be an indicator of diagnosis
and prognosis. Many researchers have shown that the
miRNA profiles in EVs are significantly different in
patients with high-metastatic tumors. The miRNAs that
may potentially be used as diagnostic and prognostic
markers are summarized in [116]. Cancer-specific markers
of EVs have been identified for application to cancer
diagnostics at early stages. Microarray analyses revealed
the accumulation of let-7a, miR-1229, miR-1246, miR-
150, miR-21, miR-223, and miR-23a in the EV-concen-
trated fraction from patients with colorectal cancer [118].
In prostate cancer, miR-141 and miR-375 are promising
markers of metastasis in the blood circulation. In particular,
miR-141 levels were shown to be 46-fold higher in meta-
static patients than healthy individuals in plasma [22, 119].
Both miRNAs were significantly increased in EVs in sera
from men with metastatic disease [120] (reviewed in [121,
122]). EVs derived from patients with ovarian cancer were
found to present a diagnostic profile of 8 miRNAs (miR-21,
miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-
205 and miR-214) [91]. In EVs from lung adenocarcinoma
patients, the profiles of 12 miRNAs (miR-17-3p, miR-21,
miR-106a, miR-146, miR-155, miR-191, miR-192, miR-
203, miR-205, miR-210, miR-212, and miR-214), which
are diagnostic in lung tumor biopsies, showed similar
pattern [123]. The profiling of miRNAs in EVs is expected
as a powerful strategy for cancer diagnosis and prognosis.
One bottleneck in the detection of miRNAs in EVs in the
arena of diagnostics is the methods used for the collection of
EVs. Collecting EVs using ultracentrifugation is a con-
ventional way to collect EVs, but it is time consuming.
Collecting EVs through filtration and affinity purification
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based on surface proteins are possible alternative strategies
[124]. For expecting clinical use, EV collection using
microfluidic immunoaffinity method that can directly bring
into transcriptome analysis has been developed [125].
Drug delivery systems
Extracellular vesicles are anticipated to be useful as a drug
delivery system to deliver anti-tumor siRNAs, as nucleic
acid medicines, specifically to cancer cells as a novel cancer
therapy [126]. Although the native targeting system is not
known, Ohno et al. engineered the surface of EVs to express
the GE11 peptide or the EGF peptide, which is specifically
recognized by EGFR. The engineered EVs were success-
fully delivered to EGFR-expressing breast cancer cells, and
the encapsulated siRNAs repressed target gene expression
[127]. Alvarez-Erviti et al. [128] also modified the surface of
the exosome to deliver siRNA to brain in mice using self-
derived exosomes from dendritic cells. For neuron-specific
targeting, Lamp2b, and exosomal membrane protein, was
fused to neuron-specific RVG peptide.
In addition, introducing exogenous siRNAs into exosome
is another important aspect for drug delivery system. Wahl-
gren et al. [129] tested several methods to introduce double-
stranded siRNA into plasma-derived exosome by electro-
poration and by chemical transfections using lipid micelles.
They showed that lipid micelles themself transfer siRNA into
cells and hard to distinguish from the delivery by exosome.
Shtam et al. [130] also used both lipofectamine and elec-
troporation to introduce siRNA into human exosomes. And
they supported that electroporation is applicable for siRNA
introduction into exosomes. Alvarez-Erviti et al. [128] used
electroporation to introduce siRNA into exosomes. However,
the efficiency of loading siRNAs by electroporation in exo-
some should be improved for drug delivery system, as the
current efficiency is lower than 30 % [129].
Together with as-yet-undeveloped technologies for the
targeted packaging of miRNAs, the targeting of EVs would
be a useful technology in developing drug delivery systems
for nucleic acid medicines.
Therapeutics
As miRNAs transferred by cancer-derived EVs are known
to promote cancer progression in many ways, the removal
of cancer-secreted EVs is assumed to represent an effec-
tive means of repressing cancer proliferation and
dissemination. Aethlon Medical Inc. has already devel-
oped a dialysis-like system that removes EVs in the
circulating blood via affinity binding to immobilized EV-
binding lectins and antibodies [131]. Although some
concerns should be addressed before this system is used
for treatment, such as how much impact the transient
reduction of cancer-derived EVs has and whether the
removal of EVs not only from cancer cells but also from
non-cancerous cells in the body has a negative impact,
this method is anticipated to serve as a novel cancer
therapy.
Conclusions and perspectives
MicroRNAs regulate gene expression levels post-trans-
criptionally. Not only do miRNAs function in the miRNA-
coding cells, but they also appear to be functional in the
recipient cells. miRNAs are secreted in a form protected by
proteins or lipid bilayer vesicles, referred to as EVs.
Increasing numbers of studies on EVs have revealed that
EVs are an important cell–cell communication tool in
biological activities and tumor progression.
EVs contain several molecules within one vesicle,
carrying not only a single type of miRNA, but various
types of miRNAs, mRNAs, proteins, and growth factors.
The ability of EVs to transfer many types of molecules at
the same time is a key feature of these vesicles compared
with protein-bound miRNAs or other secreted biomole-
cules. In addition, cells are likely to take up multiple EVs
simultaneously. Therefore, various types of molecules that
they carry could have co-operative effects on the recipient
cells. However, only a fraction of the miRNAs and
molecules responsible for certain activities in the cells are
known. To understand the true biological function of the
roles of EVs, it will be necessary to evaluate the com-
prehensive effects of EVs on cells using different
approaches.
miRNAs transferred by EVs function in tumor pro-
gression. Reducing cancer-derived EV uptake by inhibiting
secretion and eliminating EVs would provide supportive
therapeutic strategies to inhibit cancer progression and
metastasis. In addition, enhancing or mimicking cancer-
suppressive EVs could also be employed as a novel
therapy.
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